Myovant MVT-601-058 ORGOVYX

Condition: Prostate


Prostate

PROSTATE CANCER: 1 Study 

Myovant MVT-601-058 ORGOVYX – Phase 4, Multi-Center, Prospective, Observational study of patients being treated with Orgovyx  

Who’s Eligible:  

  • Patients aged 18 or older diagnosed with prostate cancer and initiating treatment with ORGOVYX at the time of enrollment or within the 1 month prior to enrollment and who remain on treatment at enrollment 
  • Patients who have reviewed and signed the informed consent form (ICF) 
  • Patients who are willing and able to complete PRO assessments during the study 

If you would like more information please contact clinical trials research coordinator at DJL Research in Charlotte 704-247-9179, x-207